F
lavocoxid is a proprietary blend of purified, plantderived bioflavonoids, including baicalin and catechins, that is marketed as a medical food used for therapy for arthritis (1) . It became available for treatment of chronic osteoarthritis in the United States in 2004. It is available only by prescription in tablets of 250 mg and 500 mg under the brand name Limbrel (Primus Pharmaceuticals, Scottsdale, Arizona) (2) . A medical food, as defined in section 5(b) of the Orphan Drug Act (21 U.S.C. 360ee [b] [3]), is "a food which is formulated to be consumed or administered enterally under the supervision of a physician and which is intended for the specific dietary management of a disease or condition for which distinctive nutritional requirements, based on recognized scientific principles, are established by medical evaluation" (3) . Medical foods differ from dietary supplements in that they are not designed for consumption by healthy individuals but as treatments for specific medical conditions. According to the product labeling, flavocoxid has few adverse effects, and double-blind, controlled trials have shown that its adverse event profile is similar to that of placebo (2) . Although mild elevations in serum liver enzyme levels have been reported (4, 5) , no reports of clinically apparent liver injury linked to flavocoxid have been published. Herein, we report 4 cases of liver injury due to flavocoxid that were found in a prospective study of patients with suspected drug-induced liver injury.
METHODS
The Drug-Induced Liver Injury Network (DILIN) is a consortium of 8 clinical centers and 1 data coordinating center. The network was established in 2004 to conduct a prospective observational study of individuals suspected to have liver injury due to prescription agents or herbal supplements (6) . The network enrolls patients with suspected drug-induced liver injury and collects clinical, biochemical, and histologic data along with serum, urine, and DNA for mechanistic studies.
We evaluated each participant for competing or coexisting causes of liver injury and adjudicated the liver injury event by using a predefined severity scale (6) . We performed a structured causality assessment that was based on expert consensus and the Roussel Uclaf Causality Assessment Method (RUCAM) (7) . Causality scores ranged from 1 (definite) to 5 (unlikely). The institutional review boards at all participating centers approved the observational study. All participants in the study provided written informed consent.
Role of the Funding Source
Investigators from the National Institute of Diabetes and Digestive and Kidney Diseases helped design the DILIN Prospective Study and helped develop the current report.
RESULTS
Between 2004 and 2010, a total of 877 patients with suspected drug-induced liver injury were enrolled in the DILIN Prospective Study. Four patients had liver injury that was attributed, at least in part, to use of flavocoxid.
(Detailed case histories of the 4 patients are provided in the Appendix, available at www.annals.org.) All 4 patients were women, aged 57 to 68 years, who were treated with flavocoxid in doses of 250 to 500 mg twice daily for arthritis or musculoskeletal pain symptoms (Table) . Within 1 to 3 months after starting flavocoxid, patients developed signs and symptoms of liver injury that included jaundice (n ϭ 3), pruritus (n ϭ 3), abdominal pain (n ϭ 3), fever (n ϭ 2), and rash (n ϭ 1). Initial total serum bilirubin levels ranging from 32.5 to 203.5 mol/L (1.9 to 11.9 mg/dL) were accompanied by marked elevations in alanine aminotransferase (ALT) levels (range, 741 to 1375 U/L) and mild to moderate increases in alkaline phosphatase (ALP) levels (range, 286 to 530 U/L). The peak serum bilirubin level, which ranged from 34.3 to 356 mol/L (2.0 to 20.8 mg/dL), was reached 2 to 13 days after initial presentation. Liver biopsies in 2 patients showed moderate acute hepatitis.
Results of tests for acute viral hepatitis (including IgM antibody to hepatitis E virus) (8) and chronic viral hepatitis and imaging studies for biliary obstruction were negative. No patients were hospitalized, although 2 underwent liver biopsy. No patients developed prolongation of the prothrombin time or signs or symptoms of hepatic failure. Each patient's liver injury began to resolve within a few days after stopping flavocoxid, and serum enzyme levels decreased to normal within 1 to 3 months of onset. No patients had evidence of chronic or ongoing liver injury or were rechallenged with flavocoxid.
Causality was assessed as very likely due to flavocoxid in 3 patients and as possibly due to flavocoxid in 1 patient. The possible case was complicated by exposure to several other agents that might have caused the injury, including pregabalin, duloxetine, and tizanidine. Three cases were ranked as moderate severity (score, 2ϩ [jaundiced but not hospitalized]) and 1 as mild severity (score, 1ϩ [serum enzyme elevations without jaundice]).
Context
Flavocoxid is a proprietary prescription medical food used to treat osteoarthritis.
Contribution
This case series describes 4 adults who developed symptoms and signs of liver injury within 3 months after initiating flavocoxid. Manifestations included marked elevations in alanine aminotransferase, alkaline phosphatase, and serum bilirubin levels that resolved within 3 to 12 weeks after flavocoxid was stopped.
Caution
The frequency of liver injury among persons receiving flavocoxid is not known.
Implication
Liver injury is a proven adverse effect of flavocoxid. ALP ϭ alkaline phosphatase; ALT ϭ alanine aminotransferase; DILIN ϭ Drug-Induced Liver Injury Network; NA ϭ not available; RUCAM ϭ Roussel Uclaf Causality Assessment Method. * Levels of ALT and ALP are both expressed as multiples of the upper limit of normal. A ratio below 2 indicates cholestatic liver injury, a ratio above 5 indicates hepatocellular liver injury, and a ratio between 2 and 5 indicates a mixed pattern. † For patient 3, time to improve Ն50% from peak could not be calculated because the results of laboratory tests between day 9 after enrollment and her 6-mo visit were not available. At Original Research Acute Liver Injury due to Flavocoxid
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DISCUSSION
In a large study of patients with suspected druginduced liver injury, we found 4 patients with reversible liver injury highly likely or possibly caused by flavocoxid. In an English-language MEDLINE search of the literature done in February 2012, we found no specific reports of liver injury due to flavocoxid, although clinical trials of the agent had reported instances of hepatotoxicity (4, 5, 9) . One 12-week randomized trial that compared flavocoxid (500 mg twice daily) with naproxen (500 mg twice daily) in 220 patients with osteoarthritis reported 16 patients with mild elevations in serum aminotransferase levels (flavocoxid, 11; naproxen, 5; P ϭ 0.08) and 12 with elevated bilirubin levels (flavocoxid, 5; naproxen, 7; P ϭ 0.18) (5) . Another open-label study of flavocoxid (500 mg twice daily) for 60 days in 1067 individuals with osteoarthritis reported liver test abnormalities in only 1 patient (0.1%) but did not provide details of the abnormalities (9) .
Postmarketing surveillance of flavocoxid done by Primus Pharmaceuticals showed 31 hepatic adverse events among 284 399 users, which suggests a possible incidence of about 0.011% of flavocoxid-induced liver injury (1). The reported adverse events included 22 instances of elevated liver enzyme levels, 6 instances of jaundice, and 3 cases of hepatitis. Clinical and biochemical features of 8 of the cases of clinically apparent liver disease provided by the manufacturer (Levy RM. Personal communication.) are shown in Appendix Table 1 (available at www.annals.org). The pattern of liver injury was hepatocellular in 2 cases, cholestatic in 1 case, mixed hepatocellular-cholestatic in 3 cases, and unknown in 2 cases. Two patients had eosinophilia and fever, suggesting drug hypersensitivity. No patients developed signs or symptoms of acute liver failure, and injury improved in all cases after flavocoxid was stopped. One patient restarted flavocoxid on her own and rapidly redeveloped liver injury.
Our report provides convincing evidence that flavocoxid is capable of causing clinically apparent, acute liver injury. In all 4 cases, we excluded other common diagnoses and the injury resolved promptly after flavocoxid was stopped. The clinical signature of flavocoxid-induced liver injury seems to be a mild to moderate, mixed hepatocellular-cholestatic hepatitis that arises 2 to 12 weeks after starting the medication and resolves rapidly once it is stopped. No reported cases were associated with signs of liver failure or death, and we found no evidence of residual or chronic injury in any patients. A proportion of the clinically apparent cases had mild evidence of hypersensitivity early in the course of illness as marked by low-grade fever, rash, and eosinophilia, but these features were not prominent and not present in all cases.
A limitation of our report is that the frequency, risk factors, and mechanisms of clinically significant liver injury due to flavocoxid could not be assessed. We speculate that hypersensitivity may play a role because immunoallergic features occurred in some patients, and flavocoxid is also associated with hypersensitivity pneumonitis (1, 10) . The primary ingredients of flavocoxid are baicalin and catechins, which are concentrated and standardized to greater than 90% purity. Baicalin is a free-B-ring flavonoid derived from the root of Scutellaria baicalensis (Chinese skullcap). Experimental data suggest that it has hepatoprotective activity against various hepatotoxic insults (11, 12) . Catechin is a flavan flavonoid. It is the stereoisomer epicatechin and is derived from the bark of Acacia catechu (Mimosa catechu). The hepatotoxic potential in humans of green tea extracts that contain catechins is well-recognized (13, 14). Two catechins contained in green tea are epigallocatechin gallate and epicatechin gallate. The former is generally believed to be responsible for the hepatotoxicity caused by green tea extracts (15) ; however, epicatechin is the flavonoid that is common to both green tea and flavocoxid, raising suspicion that it may be the ingredient that causes liver injury.
Flavocoxid differs from dietary supplements in that it was approved and is marketed as a medical food. However, like dietary supplements, medical foods do not require formal premarketing safety and efficacy studies (16) . Given its botanical ingredients, variation in the concentration of substances due to various factors, such as harvesting conditions, seasonal variations, and geographic origin, is possible. Unpredictable or unregulated concentration of such polyphenolic substances as catechins may set the stage for toxicity.
In summary, flavocoxid, a medical food used to treat osteoarthritis, is capable of causing acute liver injury that typically manifests as a mixed hepatocellular-cholestatic hepatitis arising after 1 to 3 months of use and is rapidly reversible after stopping the medication. 
Patient 1
A 58-year-old, non-Hispanic white woman presented to her physician with worsening fatigue, low-grade fever, pruritus, and dark urine approximately 10 weeks after starting flavocoxid at a dose of 500 mg twice daily for long-standing spinal stenosis and osteoarthritis. Her medical history included dyslipidemia, coronary artery disease, and mild renal insufficiency. She reported no medicinal allergies or history of adverse drug reactions. Her concomitant prescription and over-the-counter (OTC) medicines included aspirin, tramadol, omeprazole, ezetimibe, 1% oxiconazole cream, flaxseed oil, zolpidem, glucosamine, multivitamins, and calcium plus vitamin D. The findings from her physical examination were unremarkable. Laboratory tests at presentation included a normal complete blood count without eosinophilia. Her serum ALT level was 1105 U/L, aspartate aminotransferase (AST) level was 1198 U/L, ALP level was 487 U/L, and total bilirubin level was 42.7 mol/L (2.5 mg/dL). Results of these tests were normal on routine testing 2 months before and 1 month after flavocoxid was started (Appendix Table 2 ). Results of tests for acute and chronic viral hepatitis, autoantibodies, and serum immunoglobulins were unrevealing. Abdominal imaging showed no abnormalities. A liver biopsy was interpreted as compatible with drug-induced liver injury, with focal necrosis and inflammation, portal lymphocytic inflammatory infiltrates with some eosinophils, and plasma cells. She was instructed to discontinue flavocoxid. Her serum enzyme levels increased over the next 10 days, and her serum bilirubin level increased to 124.8 mol/L (7.3 mg/dL). Thereafter, her condition improved and her liver abnormalities resolved, decreasing to the normal range by 12 weeks after presentation. She was not rechallenged with flavocoxid but resumed all other medicines without any problems. In the formal assessment of causality, the DILIN investigators judged the liver injury as very likely due to flavocoxid (score, 2). The RUCAM score was 8 (probable), and the severity was scored as moderate (score, 2ϩ [jaundice without hospitalization or signs of hepatic failure]).
Patient 2
A 57-year-old, non-Hispanic white woman presented to her physician with several days' history of severe generalized pruritus, rash, and dark urine approximately 9 weeks after starting flavocoxid in a dose of 250 mg twice daily for osteoarthritis. She was known to have normal liver test results on routine testing 3 months before starting treatment. Her medical history was also significant for gastroesophageal reflux disease. Her concomitant prescription and OTC medicines included long-term use of pantoprazole (40 mg, as needed), FemHRT (Warner Chilcott, Dublin, Ireland) (1 mg norethindrone acetate and 5 mcg ethinyl estradiol), fluticasone nasal spray, aspirin, calcium with vitamin D, glucosamine, and a multivitamin. She was a nonsmoker and consumed 1 to 2 glasses of wine 3 times per week. She reported no medicinal allergies. On presentation, the findings from her physical examination were unremarkable except for a faint maculopapular rash. Laboratory tests revealed an ALT level of 741 U/L, AST level of 233 U/L, ALP level of 286 U/L, and total bilirubin level of 32.4 mol/L (1.9 mg/dL). A complete blood count was normal without eosinophilia. Results of tests for viral hepatitis were negative, and abdominal imaging showed no competing cause. Antimitochondrial antibodies were undetectable and serum globulin levels were normal, but other autoantibodies were not measured. Her primary care physician instructed her to stop flavocoxid and prescribed a short course of oral prednisone (10 mg/d, tapered over 9 days). She continued her other long-term prescription and OTC medicines. After stopping flavocoxid, her symptoms improved rapidly and her liver abnormalities resolved over the ensuing 4 weeks (Appendix Table 3 ). In the formal causality assessment, the DILIN investigators judged the liver injury as very likely due to flavocoxid (score, 2). The RUCAM score was 8 (probable), and the severity was scored as moderate (score, 2ϩ [jaundice without hospitalization or signs of hepatic failure]).
Patient 3
A 60-year-old, non-Hispanic white woman presented to her physician with several days' history of dark urine, itching, and jaundice approximately 12 weeks after starting flavocoxid (500 mg twice daily) and 7 weeks after starting pregabalin (75 mg 3 times daily) for fibromyalgia. Her medical history was also significant for hypertension, depression, gastroesophageal reflux disease, deep venous thrombosis, and benign kidney tumor. Her concomitant prescription medicines included zolpidem, duloxetine, fentanyl, oxycodone with acetaminophen, lansoprazole, ondanse- Table 4 ). In the formal assessment of causality, the DILIN investigators considered the clinical course as highly likely due to drug-induced liver injury (score, 2) but had difficulty in specifically attributing the liver injury to flavocoxid or pregabalin. The compound-specific causality score was 4 (possible) for flavocoxid and 3 (probable) for pregabalin. The RUCAM score for flavocoxid was 2 (unlikely), and the severity was scored as moderate (score, 2 [jaundiced but not hospitalized]).
Patient 4
A 67-year-old, non-Hispanic white woman presented to her physician with fatigue and dark urine 4 weeks after starting flavocoxid (500 mg twice daily) for long-standing osteoarthritis. Her other medical problems included severe obesity, atrial fibrillation, hypertension, dyslipidemia, gastroesophageal reflux disease, and the irritable bowel syndrome. Her concomitant prescription and OTC medicines included aspirin, furosemide, hydrochlorothiazide, levothyroxine, metoprolol, omeprazole, potassium, simvastatin, warfarin, calcium, fish oil, and linum seed oil. She reported no alcohol consumption. Her medicinal allergies included erythromycin, morphine, and tetracycline. The findings from her physical examination were unremarkable except for obesity. Laboratory tests at presentation revealed an ALT level of 1375 U/L, AST level of 1050 U/L, ALP level of 770 U/L, and total bilirubin level of 71.8 mol/L (4.2 mg/dL). A complete blood count was normal without eosinophilia. Results of tests for viral hepatitis were negative. Although anti-smooth muscle and mitochondrial antibodies were undetectable, antinuclear antibody was positive at 1:1280 dilution, whereas total serum globulin levels were normal. Abdominal imaging and a subsequent endoscopic retrograde cholangiopancreatography showed no evidence of biliary obstruction. A liver biopsy was not done. She was instructed to discontinue flavocoxid. She remained jaundiced for almost a month, but her condition gradually improved, and liver test results had all decreased to the normal range by 12 weeks after stopping flavocoxid (Appendix Table 5 ). In the formal causality assessment, the DILIN investigators judged the liver injury as very likely due to flavocoxid (score, 2). The RUCAM score was 9 (highly probable), and the severity was scored as moderate (score, 2 [jaundiced but not hospitalized]). 
Appendix Table 1. Summary of Cases of Potential Liver Injury due to Limbrel Reported to Primus Pharmaceuticals
